The Impact of Renal Impairment on the Pharmacokinetic and Pharmacodynamic of LEO 27847

Main Inclusion Criteria: * Male and/or non-childbearing potential female, 18 years of age and older, healthy or with stable renal impairment (deemed stable by the referring physician for at least the last 4 weeks and not expected to change significantly during the next 3 months) * BMI ≥18.0 and ≤ 42 kg/m2 * Patients with stable concomitant medical conditions * Healthy subjects or patients with a creatinine clearance (at the time of screening) estimated using the formula of Cockcroft and Gault within the range of: * ≥ 50 to ≤ 80 mL/min (Mild Group: 8 subjects), * ≥ 30 to \< 50 mL/min (Moderate Group: 8 subjects), * \< 30 mL/min (Severe Group: 8 subjects). Main Exclusion Criteria: * Patients with renal transplants or currently on haemodialysis or peritoneal dialysis * Clinically significant illness or surgery within 4 weeks prior to dosing * Clinically significant ECG abnormalities or vital sign abnormalities at screening * History of stroke, cerebrovascular disorder, coronary angioplasty and coronary bypass graft * Clinically significant history or presence of any gastrointestinal pathology * Use of medications other than their stable medications within 14 days prior to administration of investigational product or over-the-counter products within 7 days prior to administration of investigational product, except for: * multivitamins or vitamin D taken on a regular basis * topical products without systemic absorption * Hemoglobin ≤ 90 g/L * Serum total calcium (adjusted for albumin) level \< 2.25 mmol/L * Clinically significant history of congestive heart failure, cardiac dysfunction or liver disease